PFK-015

PFK-015, a derivative of 3PO, is a specific PFKFB3 inhibitor. PFK-015 inhibits recombinant PFKFB3 with an IC50 value of 110 nM and inhibits PFKFB3 activity in cancer cells with an IC50 value of 20 nM. PFK-015 can be used for the research of multiple cancers such as lung cancer, stomach cancer, colon cancer and esophageal squamous cell carcinoma (ESCC) [1][2].

Product Specifications

CAS Number

[4382-63-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy

Type

Reference compound

Related Pathways

Autophagy

Applications

Cancer-programmed cell death

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/PFK-015.html

Purity

99.80

Solubility

DMSO : 25.2 mg/mL (ultrasonic; warming)

Smiles

O=C(C1=CC=NC=C1)/C=C/C2=NC3=CC=CC=C3C=C2

Molecular Formula

C17H12N2O

Molecular Weight

260.29

Precautions

H302, H315, H319, H335

References & Citations

[1]Jia Bo Zheng, et al. Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer. Oncoimmunology. 2022 May 25;11 (1) :2079182. |[2]Brian Clem, et al. Characterization of a novel small molecule antagonist of 6-phosphofructo-2-kinase that suppresses glucose metabolism and tumor growth. ORAL PRESENTATIONS - PROFFERED ABSTRACTS| APRIL 15 2011.